Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus palliative radiotherapy for advanced non-small cell lung cancer
ACTRN12610000571077Phase 2Recruiting
- Sponsor
- YM BioSciences
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Nimotuzumab + radiotherapy with Placebo + radiotherapy (2 arms). Primary endpoint: Overall survival. Started Mar 2009; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12610000571077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000571077.